- Home
- CLH vs ABVX Comparison
CLH vs ABVX Comparison
Compare CLH & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLH | ABVX |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Environmental Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.2B |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLH | ABVX |
|---|---|---|
| Price | $261.50 | $123.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $259.25 | $130.09 |
| AVG Volume (30 Days) | 391.2K | ★ 2.0M |
| Earning Date | 02-18-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.20 | N/A |
| Revenue | ★ $5,962,257,000.00 | $6,231,374.00 |
| Revenue This Year | $2.85 | $6.80 |
| Revenue Next Year | $3.85 | N/A |
| P/E Ratio | $36.33 | ★ N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $178.29 | $4.77 |
| 52 Week High | $268.22 | $148.83 |
Technical Indicators
Market Signals| Indicator | CLH | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 64.55 | 50.00 |
| Support Level | $255.67 | $113.64 |
| Resistance Level | $264.26 | $122.50 |
| Average True Range (ATR) | 6.76 | 8.60 |
| MACD | 0.76 | -0.99 |
| Stochastic Oscillator | 78.92 | 43.88 |
Price Performance
Historical ComparisonAbout CLH Clean Harbors Inc.
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.